đŠē ADENOID HYPERTROPHY â Clinical Report Analysis & Management Plan
āĻŦāĻžāĻāϞāĻžāϝāĻŧ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āϰāĻŋāĻĒā§āϰā§āĻ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ | Report No. 1 & Report No. 2
āĻāĻĒāύāĻžāϰ āĻĻā§āĻāϝāĻŧāĻž āĻĻā§āĻāĻŋ āĻāĻŦāĻŋ āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āĻāĻŋāĨ¤ āĻĒā§āϰāĻĨāĻŽāĻāĻŋ Radiology Written Report āĻāĻŦāĻ āĻĻā§āĻŦāĻŋāϤā§āϝāĻŧāĻāĻŋ Lateral Nasopharyngeal X-ray FilmāĨ¤
đ´ āϰāĻŋāĻĒā§āϰā§āĻā§ āĻĒāĻžāĻāϝāĻŧāĻž āĻĒā§āϰāϧāĻžāύ āϰā§āĻ āύāĻŋāϰā§āĻŖāϝāĻŧ
Radiological Diagnosis: Mild to Moderate Adenoid Hypertrophy with Nasopharyngeal Airway Narrowing.
āĻŦāĻžāĻāϞāĻž: āĻļāĻŋāĻļā§āĻāĻŋāϰ āύāĻžāĻā§āϰ āĻĒā§āĻāύ⧠āĻ āĻŦāϏā§āĻĨāĻŋāϤ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻāĻŋāϏā§āϝ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻā§āϰ āϤā§āϞāύāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧā§āĻā§āĨ¤ āĻĢāϞ⧠āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻļā§āĻŦāĻžāϏ āĻāϞāĻžāĻāϞā§āϰ āĻĒāĻĨ āĻŽā§āĻĻā§ āĻĨā§āĻā§ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āϏāĻāĻā§āĻāĻŋāϤ āĻšāϝāĻŧā§āĻā§āĨ¤
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: āϞāĻŋāĻāĻŋāϤ āϰāĻŋāĻĒā§āϰā§āĻ āĻĨā§āĻā§ āĻāĻ āϰā§āĻ āύāĻŋāϰā§āĻŖāϝāĻŧ āϝāĻĨā§āώā§āĻ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĨ¤ āϤāĻŦā§ āĻļāĻŋāĻļā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻāĻŦāĻ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϞ⧠āύā§āϝāĻžāϏāĻžāϞ āĻāύā§āĻĄā§āϏā§āĻāĻĒāĻŋ āĻāĻžāĻĄāĻŧāĻž āĻĒā§āϰāĻā§āϤ āĻļā§āĻŦāĻžāϏāύāĻžāϞāĻŋāϰ āĻŦāĻžāϧāĻžāϰ āϤā§āĻŦā§āϰāϤāĻž, āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻāĻŋāĻāĻŦāĻž āĻ āĻĒāĻžāϰā§āĻļāύā§āϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
ā§§. REPORT NO. 1 â RADIOLOGY WRITTEN REPORT


đ´ Red Box Marked Report
āĻŽā§āϞ āϰāĻŋāĻĒā§āϰā§āĻā§āϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϞāĻžāĻāύāĻā§āϞ⧠āϞāĻžāϞ āĻŦāĻā§āϏ āĻĻāĻŋāϝāĻŧā§ āĻāĻŋāĻšā§āύāĻŋāϤ āĻāϰā§āĻāĻŋāĨ¤ āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻŦāĻā§āϏā§āϰ āύāĻŽā§āĻŦāϰ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒāĻžāĻļā§ āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
đˇ Report No. 1 â Red Box Marked Image with Bangla Clinical Meaning
āϰāĻŋāĻĒā§āϰā§āĻā§āϰ āĻĒā§āϰāϤāĻŋāĻāĻŋ āϞāĻžāĻāύā§āϰ Clinical Interpretation
| Original English Report | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ āĻ Clinical Significance |
|---|---|
| Digital X-ray of Nasopharynx, Lateral View | āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻ āĻāĻļā§āϰ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĻāĻŋāĻā§āϰ āĻāĻā§āϏ-āϰā§āĨ¤ |
| đ´ Soft tissue swelling is seen in posterior wall nasopharynx. | āύāĻžāϏā§āĻĢā§āϝāĻžāϰāĻŋāĻāĻā§āϏā§āϰ āĻĒā§āĻāύā§āϰ āĻĻā§āϝāĻŧāĻžāϞ⧠āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻŦāĻž āĻĢā§āϞāĻžāĻāĻžāĻŦ āĻĻā§āĻāĻž āϝāĻžāĻā§āĻā§āĨ¤ āĻāĻāĻŋ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻšāĻāϝāĻŧāĻžāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤ |
| đ´ Nasopharyngeal air column is mild to moderately compressed. | āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžāϝāĻŧā§ āĻāϞāĻžāĻāϞā§āϰ āĻĒāĻĨ āĻŽā§āĻĻā§ āĻĨā§āĻā§ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āϏāĻāĻā§āĻāĻŋāϤ āĻšāϝāĻŧā§āĻā§āĨ¤ |
| Cervical spine appears normal. | āĻāϞāĻžāϰ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻ āĻāĻļ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāϞ⧠āϰāĻŋāĻĒā§āϰā§āĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ |
| đ´ IMPRESSION: Mild to moderate adenoid hypertrophy. | āϰā§āĻĄāĻŋāĻāϞāĻāĻŋāϏā§āĻā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ: āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŽā§āĻĻā§ āĻĨā§āĻā§ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧā§āĻā§āĨ¤ |
đŦ Abnormal Findings
Abnormality 1: Adenoid Enlargement
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻšāϞ⧠Nasopharynx-āĻāϰ āĻāĻĒāϰā§āϰ āĻ āĻĒā§āĻāύā§āϰ āĻ āĻāĻļā§ āĻ āĻŦāϏā§āĻĨāĻŋāϤ lymphoid tissue, āϝāĻž āĻļāĻŋāĻļā§āϰ āϰā§āĻāĻĒā§āϰāϤāĻŋāϰā§āϧ āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāϰ āĻ āĻāĻļāĨ¤
āĻāĻ āĻļāĻŋāĻļā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻāĻŋ āĻŦāĻĄāĻŧ āĻšāĻāϝāĻŧāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§āĨ¤
Abnormality 2: Nasopharyngeal Airway Narrowing
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻšāĻāϝāĻŧāĻžāϰ āĻāĻžāϰāĻŖā§ āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤ āĻšāϝāĻŧā§āĻā§āĨ¤
āĻāϰ āĻĢāϞ⧠āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻž, āĻŽā§āĻ āĻĻāĻŋāϝāĻŧā§ āĻļā§āĻŦāĻžāϏ āύā§āĻāϝāĻŧāĻž āĻŦāĻž āύāĻžāĻ āĻĄāĻžāĻāĻžāϰ āĻŽāϤ⧠āĻāĻĒāϏāϰā§āĻ āĻĻā§āĻāĻž āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ X-ray-āĻ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤ āĻĒāĻžāĻāϝāĻŧāĻž āĻŽāĻžāύā§āĻ āĻļāĻŋāĻļā§āĻāĻŋāϰ Obstructive Sleep Apnea āϰāϝāĻŧā§āĻā§, āĻāĻŽāύ āύāϝāĻŧāĨ¤
⧍. REPORT NO. 2 â LATERAL NASOPHARYNGEAL X-RAY FILM


đ´ Red Box Marked X-ray
đˇ Report No. 2 â X-ray Film Marked with Red Boxes and Bangla Explanation
X-ray-āĻāϰ āĻŦā§āϝāĻžāĻā§āϝāĻž
đ´ Box 1: Nasopharyngeal Region
āĻāĻ āĻŦāĻā§āϏ⧠āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨā§āϰ āĻļāĻžāϰā§āϰāϏā§āĻĨāĻžāύāĻŋāĻ āĻ āĻā§āĻāϞ āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
āĻāĻāĻŋ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄā§āϰ āύāĻŋāϰā§āĻā§āϞ āϏā§āĻŽāĻžāύāĻž āύāϝāĻŧāĨ¤
đ´ Box 2: Image Glare
āĻāĻ āĻ āĻāĻļā§ āĻāϞ⧠āĻĒā§āϰāϤāĻŋāĻĢāϞāĻŋāϤ āĻšāϝāĻŧā§āĻā§āĨ¤ āĻāĻāĻŋ āĻā§āύ⧠āϰā§āĻā§āϰ āϞāĻā§āώāĻŖ āύāϝāĻŧ, āϤāĻŦā§ āĻāĻŦāĻŋāϰ āĻāĻŋāĻā§ āĻ āĻāĻļ āĻ āϏā§āĻĒāώā§āĻ āĻāϰā§āĻā§āĨ¤
Clinical Interpretation
āĻĻā§āĻŦāĻŋāϤā§āϝāĻŧ āĻāĻŦāĻŋāĻāĻŋ āĻŽā§āĻŦāĻžāĻāϞ⧠āϤā§āϞāĻž X-ray film-āĻāϰ āĻāĻŦāĻŋāĨ¤ āĻāϤ⧠āĻāϞā§āϰ āĻĒā§āϰāϤāĻŋāĻĢāϞāύ āĻ āĻāĻŦāĻŋāϰ āĻŽāĻžāύā§āϰ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āϰāϝāĻŧā§āĻā§āĨ¤
āϤāĻžāĻ āĻāĻ āĻāĻŦāĻŋ āĻĨā§āĻā§ āϏā§āĻŦāĻžāϧā§āύāĻāĻžāĻŦā§ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄā§āϰ āύāĻŋāϰā§āĻā§āϞ āĻŽāĻžāĻĒ, obstruction percentage āĻ āĻĨāĻŦāĻž endoscopic grade āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
āĻĒā§āϰāĻĨāĻŽ āϰāĻŋāĻĒā§āϰā§āĻā§ āϝ⧠mild-to-moderate adenoid hypertrophy āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§, āϏā§āĻāĻŋāĻ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āϏāĻŦāĻā§āϝāĻŧā§ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ radiological findingāĨ¤
ā§Š. FINAL DIAGNOSIS â PRESCRIPTION-āĻ āĻā§ āϞāĻŋāĻāĻŦā§āύ?
â Radiological Diagnosis
Adenoid Hypertrophy (Mild to Moderate)
ICD-10-CM: J35.2 â Hypertrophy of Adenoids
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āϝāĻžāϝāĻŧ:
Provisional Dx: Adenoid Hypertrophy with Radiographic Nasopharyngeal Airway Narrowing.
āĻŦāĻžāĻāϞāĻž:
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻšāϝāĻŧā§ āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤ āĻšāĻāϝāĻŧāĻžāĨ¤
Diagnostic Confidence
| Assessment | Confidence |
|---|---|
| āϰāĻŋāĻĒā§āϰā§āĻā§ Mild to Moderate Adenoid Hypertrophy āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§ | 0.99 |
| Radiological diagnosis āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻšāĻžāĻāĻĒāĻžāϰāĻā§āϰāĻĢāĻŋāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ | 0.95 |
| āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻŋāĻā§ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤ āĻšāϝāĻŧā§āĻā§ | 0.90 |
| āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖ | āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāϝāĻŧāύāĻŋ |
| Obstructive Sleep Apnea āϰāϝāĻŧā§āĻā§ | āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻ |
| āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ | āĻŦāϰā§āϤāĻŽāĻžāύ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāϝāĻŧāύāĻŋ |
ā§Ē. ETIOLOGY / PATHOPHYSIOLOGY
āĻā§āύ Adenoid Hypertrophy āĻšāϝāĻŧ?
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻšāĻāϝāĻŧāĻžāϰ āĻĒā§āĻāύ⧠āĻāĻāĻžāϧāĻŋāĻ āĻāĻžāϰāĻŖ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
| Possible Causes | Clinical Explanation |
|---|---|
| Recurrent upper respiratory infections | āĻŦāĻžāϰāĻŦāĻžāϰ āĻāĻžāĻāϰāĻžāϞ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĢāϞ⧠lymphoid tissue āĻŦāĻĄāĻŧ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ |
| Chronic inflammation | āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻĒā§āϰāĻĻāĻžāĻšā§ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻāĻŋāϏā§āϝā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ |
| Allergic rhinitis | āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύ āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻžāϰ āϏāĻŽāϏā§āϝāĻž āĻŦāĻžāĻĄāĻŧāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ |
| Physiological lymphoid enlargement | āĻļāĻŋāĻļā§āϰ āĻŦāϝāĻŧāϏ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϰā§āĻāĻĒā§āϰāϤāĻŋāϰā§āϧ āĻāĻžāϰā§āϝāĻā§āϰāĻŽā§āϰ āĻ āĻāĻļ āĻšāĻŋāϏā§āĻŦā§ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻŦāĻĄāĻŧ āĻĨāĻžāĻā§āĨ¤ |
| Repeated antigenic stimulation | āĻā§āĻŦāĻžāĻŖā§ āĻ āĻĒāϰāĻŋāĻŦā§āĻļāĻāϤ āĻŦāĻŋāĻāĻŋāύā§āύ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻā§āύā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļā§ lymphoid tissue āĻŦā§āĻĻā§āϧāĻŋ āĻĒā§āϤ⧠āĻĒāĻžāϰā§āĨ¤ |
āĻāĻ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āϰāĻŋāĻĒā§āϰā§āĻ āĻĨā§āĻā§ āĻāĻžāύāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, chronic adenoiditis āĻ āĻĨāĻŦāĻž recurrent infection āĻāĻā§ āĻāĻŋ āύāĻž, āϤāĻž āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻšāϞ⧠āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨā§ āĻŦāĻžāϧāĻž āϤā§āϰāĻŋ āĻšāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŦāĻ Eustachian tube-āĻāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāĻ āĻŦāĻŋāĻā§āύāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻĢāϞ⧠āĻāĻŋāĻā§ āĻļāĻŋāĻļā§āϰ middle-ear effusion āĻ conductive hearing loss āĻĻā§āĻāĻž āĻĻā§āϝāĻŧāĨ¤
ā§Ģ. CLINICAL FEATURES â āϰā§āĻā§āϰ āĻā§ āĻā§ āĻāĻĒāϏāϰā§āĻ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§?
āĻāĻ āĻļāĻŋāĻļā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāĻĒāϏāϰā§āĻ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋāĨ¤ āύāĻŋāĻā§āϰ āϞāĻā§āώāĻŖāĻā§āϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻāĻā§ āĻāĻŋāĻā§āĻāĻžāϏāĻž āĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
| Clinical Feature | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ |
|---|---|
| Nasal obstruction | āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻž |
| Mouth breathing | āĻŽā§āĻ āĻĻāĻŋāϝāĻŧā§ āĻļā§āĻŦāĻžāϏ āύā§āĻāϝāĻŧāĻž |
| Snoring | āĻā§āĻŽā§āϰ āϏāĻŽāϝāĻŧ āύāĻžāĻ āĻĄāĻžāĻāĻž |
| Sleep-disordered breathing | āĻā§āĻŽā§āϰ āϏāĻŽāϝāĻŧ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏ |
| Witnessed apnea | āĻā§āĻŽā§āϰ āϏāĻŽāϝāĻŧ āĻļā§āĻŦāĻžāϏ āĻŦāύā§āϧ āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āĻāĻāύāĻž |
| Recurrent rhinorrhea | āĻŦāĻžāϰāĻŦāĻžāϰ āύāĻžāĻ āĻĻāĻŋāϝāĻŧā§ āĻĒāĻžāύāĻŋ āĻŦāĻž āϏāϰā§āĻĻāĻŋ āĻĒāĻĄāĻŧāĻž |
| Hyponasal voice | āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāϞ⧠āϝā§āĻŽāύ āĻāĻĨāĻž āĻļā§āύāĻžāϝāĻŧ |
| Hearing impairment | āĻāĻžāύ⧠āĻāĻŽ āĻļā§āύāĻž |
| Recurrent otitis media | āĻŦāĻžāϰāĻŦāĻžāϰ āĻŽāϧā§āϝāĻāϰā§āĻŖā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ |
| Daytime tiredness/poor attention | āĻĻāĻŋāύā§āϰ āĻŦā§āϞāĻžāϝāĻŧ āĻā§āϞāĻžāύā§āϤāĻŋ āĻŦāĻž āĻŽāύā§āϝā§āĻ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻž |
āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻĨāĻžāĻāϞā§āĻ āϏāĻŦ āĻļāĻŋāĻļā§āϰ āĻāϏāĻŦ āĻāĻĒāϏāϰā§āĻ āĻšāϝāĻŧ āύāĻžāĨ¤
ā§Ŧ. ADDITIONAL INVESTIGATIONS
āĻāĻāύ āĻā§āύ āĻĒāϰā§āĻā§āώāĻž āϏāĻŦāĻā§āϝāĻŧā§ āĻĒā§āϰāϝāĻŧā§āĻāύ?
| Investigation | Clinical Indication |
|---|---|
| Flexible Nasopharyngoscopy | āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄā§āϰ āĻāĻāĻžāϰ, āĻ āĻŦāϏā§āĻĨāĻžāύ āĻāĻŦāĻ āĻŦāĻžāϝāĻŧā§āĻĒāĻĨā§ āĻŦāĻžāϧāĻžāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻžāĨ¤ |
| Anterior Rhinoscopy | āύāĻžāĻā§āϰ āĻā§āϤāϰ⧠allergic rhinitis, turbinate hypertrophy āĻŦāĻž āĻ āύā§āϝ āĻŦāĻžāϧāĻž āĻāĻā§ āĻāĻŋ āύāĻž āĻĻā§āĻāĻžāĨ¤ |
| Otoscopy | āĻŽāϧā§āϝāĻāϰā§āĻŖā§ āϤāϰāϞ āĻāĻŽā§āĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻžāĨ¤ |
| Tympanometry | Eustachian tube dysfunction āĻŦāĻž middle-ear effusion āϏāύā§āĻĻā§āĻš āĻšāϞā§āĨ¤ |
| Pure Tone Audiometry | āĻļā§āϰāĻŦāĻŖāĻļāĻā§āϤāĻŋ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āĻ āĻāĻŋāϝā§āĻ āĻĨāĻžāĻāϞ⧠āĻŦāϝāĻŧāϏā§āĻĒāϝā§āĻā§ hearing assessmentāĨ¤ |
| Polysomnography | āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āύāĻžāĻ āĻĄāĻžāĻāĻž, āĻā§āĻŽā§āϰ āĻŽāϧā§āϝ⧠āĻļā§āĻŦāĻžāϏ āĻŦāύā§āϧ āĻšāĻāϝāĻŧāĻž āĻŦāĻž OSA-āĻāϰ āϞāĻā§āώāĻŖ āĻĨāĻžāĻāϞā§āĨ¤ |
| Allergy Testing | āĻāϤāĻŋāĻšāĻžāϏ⧠allergic rhinitis-āĻāϰ āĻļāĻā§āϤ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĨāĻžāĻāϞ⧠āĻāĻŦāĻ āĻĢāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āĻāĻŽāύ āĻā§āώā§āϤā§āϰā§āĨ¤ |
āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āĻā§āώāĻž
ENT examination Âą Flexible Nasopharyngoscopy
āύā§āϝāĻžāϏā§āĻāύā§āĻĄā§āϏā§āĻāĻĒāĻŋ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āϏāϰāĻžāϏāϰāĻŋ āĻĻā§āĻāϤ⧠āĻāĻŦāĻ āĻ āύā§āϝ āϰā§āĻ āĻĨā§āĻā§ āĻĒā§āĻĨāĻ āĻāϰāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
āϤāĻŦā§ āϏāĻŦ āĻļāĻŋāĻļā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻāĻŋ āĻŦāĻžāϧā§āϝāϤāĻžāĻŽā§āϞāĻ āύāϝāĻŧ; āĻļāĻŋāĻļā§āϰ āϏāĻšāϝā§āĻāĻŋāϤāĻž, āĻāĻĒāϏāϰā§āĻ āĻāĻŦāĻ ENT āĻĒāϰā§āĻā§āώāĻžāϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāĨ¤
āĻāĻ āϰāĻŋāĻĒā§āϰā§āĻ āĻĒāĻžāĻāϝāĻŧāĻžāϰ āĻĒāϰ āύāĻŋāϝāĻŧāĻŽāĻŋāϤāĻāĻžāĻŦā§ āĻāĻŦāĻžāϰ X-ray āĻŦāĻž CT scan āĻāϰāĻžāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āύā§āĻāĨ¤ āĻŦāĻŋāĻļā§āώ āĻā§āύ⧠āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ imaging āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻŦā§āύāĨ¤
ā§. DIFFERENTIAL DIAGNOSIS
āϝāĻĻāĻŋāĻ āϰāĻŋāĻĒā§āϰā§āĻ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻšāĻžāĻāĻĒāĻžāϰāĻā§āϰāĻĢāĻŋāϰ āĻĒāĻā§āώā§, āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻžāϰ āĻ āύā§āϝ āĻāĻžāϰāĻŖāĻā§āϞā§āĻ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
| Differential Diagnosis | āĻāĻāύ āϏāύā§āĻĻā§āĻš āĻāϰāĻŦā§āύ? |
|---|---|
| Allergic rhinitis | āĻšāĻžāĻāĻāĻŋ, āύāĻžāĻ āĻā§āϞāĻāĻžāύā§, āϏā§āĻŦāĻā§āĻ āϏāϰā§āĻĻāĻŋ |
| Chronic adenoiditis | āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻŦāĻž āĻĒā§āύāϰāĻžāĻŦā§āϤā§āϤ āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϞāĻā§āώāĻŖ |
| Inferior turbinate hypertrophy | āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ turbinate āĻŦāĻĄāĻŧ āĻĒāĻžāĻāϝāĻŧāĻž |
| Tonsillar hypertrophy | āĻŽā§āĻāĻāĻšā§āĻŦāϰ⧠āĻŦāĻĄāĻŧ tonsil āĻāĻŦāĻ āĻā§āĻŽā§āϰ āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏā§āϰ āϏāĻŽāϏā§āϝāĻž |
| Chronic rhinosinusitis | āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āύāĻžāĻ āĻŦāύā§āϧ, āϏāϰā§āĻĻāĻŋ, āĻāĻžāĻļāĻŋ |
| Choanal stenosis | āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻĒāĻĨā§āϰ āĻāĻ āύāĻāϤ āϏāĻāĻā§āϰā§āĻŖāϤāĻž |
| Nasopharyngeal mass | āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻāĻĒāĻžāĻļā§āϰ āĻŦāĻžāϧāĻž, āϰāĻā§āϤāĻĒāĻžāϤ āĻŦāĻž āĻ āύā§āϝ āϏāϤāϰā§āĻāϤāĻžāĻŽā§āϞāĻ āϞāĻā§āώāĻŖ |
āĻāĻ āĻŦāϝāĻŧāϏ⧠adenoid hypertrophy āĻāĻāĻāĻŋ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ āĻĒā§āϰāϧāĻžāύ diagnosisāĨ¤ āϤāĻŦā§ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻĒāϏāϰā§āĻ āĻĨāĻžāĻāϞ⧠āĻ āύā§āϝ āĻāĻžāϰāĻŖ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āĻāϰā§āϰāĻŋāĨ¤
ā§Ž. TREATMENT PLAN â Guideline-Based Management
A. Conservative Management
āĻļāĻŋāĻļā§āϰ āĻāĻĒāϏāϰā§āĻ āϝāĻĻāĻŋ āĻŽā§āĻĻā§ āĻšāϝāĻŧ āĻāĻŦāĻ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ sleep apnea, hearing loss āĻ āĻĨāĻŦāĻž persistent ear disease āύāĻž āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āĻĒā§āϰāĻĨāĻŽā§ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϤāϤā§āϤā§āĻŦāĻžāĻŦāϧāĻžāύ⧠conservative management āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Normal saline nasal spray: āύāĻžāĻ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻ āϏāϰā§āĻĻāĻŋ/āĻāĻŽā§ āĻĨāĻžāĻāĻž secretion āĻāĻŽāĻžāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤ āĻāĻāĻŋ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻāĻŋāϏā§āϝ⧠āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻā§āĻ āĻāϰ⧠āĻĻā§āϝāĻŧ āύāĻžāĨ¤
Allergic rhinitis āĻĨāĻžāĻāϞā§: Intranasal corticosteroid āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
āĻāĻĻāĻžāĻšāϰāĻŖ āĻšāĻŋāϏā§āĻŦā§, ⧍âā§§ā§§ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āĻļāĻŋāĻļā§āϰ allergic rhinitis-āĻāϰ āĻā§āώā§āϤā§āϰ⧠mometasone furoate nasal spray 50 microgram āĻĒā§āϰāϤāĻŋ āύāĻžāϏāĻžāϰāύā§āϧā§āϰ⧠āĻāĻ āϏā§āĻĒā§āϰ⧠āĻāϰ⧠āĻĻā§āύāĻŋāĻ āĻāĻāĻŦāĻžāϰ āĻāĻāĻāĻŋ āĻ āύā§āĻŽā§āĻĻāĻŋāϤ dosing regimenāĨ¤ āϤāĻŦā§ āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāώā§āϧ āĻļā§āϰ⧠āĻāϰāĻžāϰ āĻāĻā§ history, nasal examination āĻ contraindications āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻāĻ āĻĄā§āĻāĻāĻŋ allergic rhinitis-āĻāϰ āĻāύā§āϝ, āĻā§āĻŦāϞ X-ray-āĻ āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻŦāĻĄāĻŧ āĻĻā§āĻāĻžāϰ āĻāύā§āϝ āϏā§āĻŦāϝāĻŧāĻāĻā§āϰāĻŋāϝāĻŧ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύāϝāĻŧāĨ¤
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āύāϤā§āύ āĻāĻŦā§āώāĻŖāĻž
⧍ā§Ļ⧍ā§Ŧ āϏāĻžāϞ⧠JAMA Pediatrics-āĻ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ MIST+ randomized trial-āĻ āĻļāĻŋāĻļā§āĻĻā§āϰ obstructive sleep-disordered breathing-āĻāϰ āĻā§āώā§āϤā§āϰ⧠saline āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻĒāϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ intranasal mometasone āĻĻāĻŋāϝāĻŧā§ saline-āĻāϰ āϤā§āϞāύāĻžāϝāĻŧ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āĻŦāĻžāĻĄāĻŧāϤāĻŋ āĻāĻĒāĻāĻžāϰ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
āϤāĻžāĻ intranasal steroid āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄā§āϰ āĻāĻžāϰāĻŖā§ āĻšāĻāϝāĻŧāĻž āϏāĻŦ breathing problem-āĻ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻāĻžāϰā§āϝāĻāϰâāĻāĻŽāύ āĻĻāĻžāĻŦāĻŋ āĻāϰāĻž āĻ āĻŋāĻ āύāϝāĻŧāĨ¤
āϝā§āϏāĻŦ āĻāώā§āϧ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻĒā§āϰāϝāĻŧā§āĻāύ āύā§āĻ
āĻļā§āϧ⧠adenoid hypertrophy āĻĨāĻžāĻāϞā§āĻ systemic steroid, antibiotic āĻŦāĻž antihistamine āĻĻā§āĻāϝāĻŧāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĻāĨ¤
Antibiotic āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϞ⧠āϤāĻžāϰ āĻĒā§āĻĨāĻ infectious indication āĻĨāĻžāĻāϤ⧠āĻšāĻŦā§āĨ¤ Antihistamine āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰ⧠āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠allergic rhinitis-āĻāϰ āĻāĻĒāϏāϰā§āĻā§āϰ āĻāύā§āϝāĨ¤
B. Surgical Management
Adenoidectomy āĻāĻāύ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻŦā§āύ?
Adenoidectomy āĻšāϞ⧠āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻŦāĻĄāĻŧ āĻšāĻāϝāĻŧāĻž āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ āĻāĻŋāϏā§āϝ⧠āĻ āĻĒāϏāĻžāϰāĻŖāĨ¤
AAO-HNS clinical indicators āĻ āύā§āϝāĻžāϝāĻŧā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ surgical indications-āĻāϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§:
- āĻ āύā§āϤāϤ āϤāĻŋāύ āĻŽāĻžāϏ āϧāϰ⧠nasal obstruction-āĻāϰ āϏāĻā§āĻā§ sleep disturbanceāĨ¤
- Persistent otitis media with effusionāĨ¤
- āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āύāĻž āĻāĻŽāĻž chronic/recurrent adenoiditisāĨ¤
- āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ hyponasal speechāĨ¤
- āĻ ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧā§āĻĄ-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ dental āĻŦāĻž facial growth disturbanceāĨ¤
- āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ complicationsāĨ¤
āĻāĻ āĻļāĻŋāĻļā§āϰ X-ray-āĻ Mild to Moderate Adenoid Hypertrophy āĻĨāĻžāĻāϞā§āĻ Adenoidectomy āĻāϰāϤ⧠āĻšāĻŦā§âāĻāĻŽāύ āύāϝāĻŧāĨ¤
āĻ āĻĒāĻžāϰā§āĻļāύā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āĻŽā§āϞāϤ āĻāĻĒāϏāϰā§āĻ, āĻāĻžāύā§āϰ āϏāĻŽāϏā§āϝāĻž, āĻā§āĻŽā§āϰ āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏ, āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒāϰā§āĻā§āώāĻž āĻāĻŦāĻ conservative treatment-āĻāϰ āĻĢāϞāĻžāĻĢāϞā§āϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰāĻŦā§āĨ¤
āϝāĻĻāĻŋ confirmed obstructive sleep apnea-āĻāϰ āϏāĻā§āĻā§ tonsillar hypertrophy-āĻ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠ENT specialist adenotonsillectomy āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
⧝. DOCTOR’S ACTION PLAN â āĻāĻāύ āĻāĻŋāĻāĻŋā§āϏāĻ āĻā§ āĻāϰāĻŦā§āύ?
āĻĒā§āϰāĻĨāĻŽ āĻāĻŋāĻāĻŋāĻā§: āĻļāĻŋāĻļā§āϰ nasal obstruction, mouth breathing, snoring, witnessed apnea, recurrent infection, hearing difficulty āĻ allergy-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Clinical examination: āύāĻžāĻ, tonsil, palate, oropharynx, lymph node āĻ āĻĻā§āĻ āĻāĻžāύ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻŦāϝāĻŧāϏ āĻ āύā§āϝāĻžāϝāĻŧā§ growth assessment-āĻ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻāĨ¤
āĻĒāϰāĻŦāϰā§āϤ⧠āĻĒāĻĻāĻā§āώā§āĻĒ: Pediatric ENT consultation āĻāϰ⧠āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ flexible nasopharyngoscopy āĻāĻŦāĻ ear assessment āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Mild symptoms āĻĨāĻžāĻāϞā§: Saline āĻ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠allergic rhinitis-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻāĻŋāϝāĻŧā§ āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĨ¤
Significant symptoms āĻĨāĻžāĻāϞā§: ENT assessment āĻāĻŦāĻ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ hearing test āĻŦāĻž sleep studyāĨ¤ āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āĻāύā§āύāϤāĻŋ āύāĻž āĻšāϞ⧠surgery-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĨ¤
āĻāϰā§āϰāĻŋ āϏāϤāϰā§āĻāϤāĻž: āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧠āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āĻāώā§āĻ, āĻ ā§āĻāĻ āύā§āϞ āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž, āĻĻā§āϰā§āĻāĻā§āώāĻŖ āĻļā§āĻŦāĻžāϏ āĻŦāύā§āϧ āĻĨāĻžāĻāĻž, āĻ āĻĨāĻŦāĻž āĻā§āĻŽā§āϰ āĻŽāϧā§āϝ⧠āĻā§āϰā§āϤāϰ āĻļā§āĻŦāĻžāϏāĻāώā§āĻ āĻĨāĻžāĻāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
ā§§ā§Ļ. REFERRAL â āĻā§āύ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāĻžāĻā§ āĻĒāĻžāĻ āĻžāĻŦā§āύ?
â Recommended Specialist
Consultant ENT & Head-Neck Surgeon
āĻŦāĻŋāĻļā§āώāϤ āĻļāĻŋāĻļā§āĻĻā§āϰ ENT āϰā§āĻā§āϰ āĻ āĻāĻŋāĻā§āĻāϤāĻž āĻāĻā§ āĻāĻŽāύ specialistāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠referral note āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āϝāĻžāϝāĻŧ: Clinical ENT Referral Note
To: Consultant ENT & Head-Neck Surgeon
Re: Evaluation of Adenoid Hypertrophy
Patient: 10-year-old male
Provisional Diagnosis: Adenoid hypertrophy with radiographic nasopharyngeal airway narrowing (ICD-10-CM: J35.2).
Investigations: Lateral nasopharyngeal X-ray dated 12 October 2026.
Radiological Findings:
- Soft tissue swelling at the posterior nasopharyngeal wall.
- Mild to moderate compression of the nasopharyngeal air column.
- Impression: Mild to moderate adenoid hypertrophy.
Clinical History: Presenting symptoms and relevant clinical examination findings are not yet documented.
Reason for Referral:
Kindly evaluate the patient clinically for symptomatic adenoid hypertrophy and associated upper airway obstruction.
Please assess the nasal airway, palatine tonsils and middle-ear status. Flexible nasopharyngoscopy may be performed if clinically indicated.
Assessment for sleep-disordered breathing, otitis media with effusion and hearing impairment is requested as appropriate.
Kindly advise regarding conservative management versus surgical intervention based on clinical findings.
Thank you.
ā§§ā§§. OVERVIEW / FINAL CLINICAL SUMMARY
| Clinical Parameter | Assessment |
|---|---|
| Patient | 10-year-old male |
| Investigation | X-ray Nasopharynx, Lateral View |
| Report Date | 12 October 2026 |
| Main Abnormality | Enlarged adenoid tissue |
| Airway Finding | Mild to moderate narrowing |
| Radiological Diagnosis | Mild to Moderate Adenoid Hypertrophy |
| ICD-10-CM | J35.2 |
| Confirmed Cause | Not established |
| Confirmed Sleep Apnea | Not established |
| First Specialist | ENT & Head-Neck Surgeon |
| Priority Investigation | ENT examination Âą Flexible Nasopharyngoscopy |
| Treatment | Symptom-directed; conservative or surgical according to clinical indications |
đ¯ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻŽāĻžāϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ Diagnosis
Provisional Dx: Adenoid Hypertrophy (J35.2)
Supporting investigation: X-ray evidence of mild-to-moderate adenoid hypertrophy with nasopharyngeal airway narrowing.
āĻāĻāĻŋāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āϤāĻĨā§āϝ āĻ āύā§āϝāĻžāϝāĻŧā§ āϏāĻŦāĻā§āϝāĻŧā§ āϝāĻĨāĻžāϝāĻĨ āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤāĻāĻžāĻŦā§ āϏāĻŽāϰā§āĻĨāύāϝā§āĻā§āϝ diagnosisāĨ¤
⧧⧍. ACTIONABLE PLAN
āĻŦāϰā§āϤāĻŽāĻžāύ āĻĒāϰāĻžāĻŽāϰā§āĻļ: āĻĒā§āϰāĻĨāĻŽā§ ENT specialist-āĻāϰ clinical assessment āĻāϰāĻžāύ⧠āĻāĻāĻŋāϤāĨ¤ āĻļā§āϧ⧠āĻāĻ X-ray āĻĻā§āĻā§ āĻ āĻĒāĻžāϰā§āĻļāύ āĻŦāĻž āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ āĻāώā§āϧā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āĻ āĻŋāĻ āĻšāĻŦā§ āύāĻžāĨ¤
āϝāĻĻāĻŋ āĻļāĻŋāĻļā§āϰ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āύāĻžāĻ āĻĄāĻžāĻāĻž, āĻā§āĻŽā§ āĻļā§āĻŦāĻžāϏ āĻŦāύā§āϧ āĻšāĻāϝāĻŧāĻž, āĻŽā§āĻ āĻĻāĻŋāϝāĻŧā§ āĻļā§āĻŦāĻžāϏ āύā§āĻāϝāĻŧāĻž āĻāĻŋāĻāĻŦāĻž āĻāĻžāύ⧠āĻāĻŽ āĻļā§āύāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āϏā§āĻā§āϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒā§āϰāĻāĻžāĻŦ āĻĢā§āϞāĻŦā§āĨ¤
REFERENCES â TEXTBOOKS, GUIDELINES & JOURNALS
Textbook references
- Cummings Otolaryngology: Head and Neck Surgery. 7th ed. Elsevier; 2021. Pediatric upper airway and adenotonsillar disease sectionsāĨ¤
- Nelson Textbook of Pediatrics. 22nd ed. Elsevier; 2024. Pediatric upper airway obstruction and sleep-disordered breathing sectionsāĨ¤
Clinical guidelines and peer-reviewed evidence
- Ahmad Z, et al. Adenoid hypertrophyâdiagnosis and treatment: the new S2k guideline. HNO. 2023;71(Suppl 1):67â72. DOI: 10.1007/s00106-023-01299-6.
- American Academy of OtolaryngologyâHead and Neck Surgery. Clinical Indicators: Adenoidectomy. 2014. āĻŦāϰā§āϤāĻŽāĻžāύ⧠āϏāĻāϏā§āĻĨāĻžāϰ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻžāϧā§āύ āύāĻŋāϰā§āĻĻā§āĻļāĻ āĻĻāϞāĻŋāϞāĨ¤
- Marcus CL, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. Pediatrics. 2012;130(3):576â584. DOI: 10.1542/peds.2012-1671.
- Nixon GM, et al. Intranasal Treatments for Children With Sleep-Disordered Breathing: The MIST+ Randomized Clinical Trial. JAMA Pediatrics. 2026;180(3):240â249. DOI: 10.1001/jamapediatrics.2025.5717.
- Sousa-Pinto B, et al. ARIA-EAACI Guidelinesâ2024â2025 Revision: Part IâGuidelines on Intranasal Treatments. Allergy. DOI: 10.1111/all.70131.
Prescription attached:-

đŠē LIPU MED â FULL BILINGUAL CLINICAL CASE REVIEW
TC(1472).(12) ¡ ENT Department Case No (109) ¡ Website-sequence-checked draft
Adenoid Hypertrophy with Physician-Documented Adenotonsillitis & Possible Otitis Media
āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻŦā§ āĻšāĻā§āĻž, āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻ ā§āϝāĻžāĻĄāĻŋāύā§-āĻāύāϏāĻŋāϞāĻžāĻāĻāĻŋāϏ āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽāϧā§āϝāĻāϰā§āĻŖā§āϰ āϰā§āĻ
1 Prescription ¡ 2 Radiology Inputs ¡ 17 Sections ¡ MedEx Sources
01. Case identification, TC, department | āĻā§āϏ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ, āĻāĻŋāϏāĻŋ āĻ āĻŦāĻŋāĻāĻžāĻ
Proposed publication title â TC(1472).(12). ENT Department Case No (109): Radiographically Confirmed Adenoid Hypertrophy with Physician-Documented Adenotonsillitis and Possible Concurrent Otitis Media â Pediatric Prescription Safety Review (1 Prescription + 2 Reports). Confidence: 0.99 (website sequence at verification time)
TC = Total Case â āϏāϰā§āĻŦāĻŽā§āĻ āĻā§āϏā§āϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āϏāĻŋāϰāĻŋā§āĻžāϞ; DCS = 12 â ENT āĻŦāĻŋāĻāĻžāĻā§āϰ āĻā§āϝāĻžāĻā§āĻāϰāĻŋ āϏāĻŋāϰāĻŋā§āĻžāϞ; Department Case No = 109 â āύāϤā§āύ ENT āĻā§āϏā§āϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰāĨ¤ āĻā§ā§āĻŦāϏāĻžāĻāĻā§ āĻĻā§āĻāĻž āϏāϰā§āĻŦāĻļā§āώ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻĒā§āϏā§āĻ TC(1471), ENT Department Case 108; āϤāĻžāĻ TC(1472)/ENT109 āĻļā§āϧ⧠āύāϤā§āύ āĻāϏā§āĻžāϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦ, āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āύāĻŽā§āĻŦāϰ āĻāĻŦāĻžāϰ āĻŽāĻŋāϞāĻŋā§ā§ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
| Original source field | āĻŽā§āϞ āύāĻĨāĻŋ | Documented value | āύāĻĨāĻŋāĻā§āĻā§āϤ āϤāĻĨā§āϝ |
|---|---|
| Patient name | āύāĻžāĻŽ | Radiology: Md. Mahamud; prescription print: MAH,MUD (āĻŦāĻžāύāĻžāύ⧠āĻā§āϏāĻā§āĻĻā§ āĻĒāĻžāϰā§āĻĨāĻā§āϝ)āĨ¤ |
| Age / sex | āĻŦā§āϏ/āϞāĻŋāĻā§āĻ | 10 years / Male â ā§§ā§Ļ āĻŦāĻāϰ / āĻā§āϞā§āĨ¤ |
| Institution | āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ | National Institute of ENT, Tejgaon, Dhaka, Bangladesh â āĻāĻžāϤā§ā§ āύāĻžāĻ-āĻāĻžāύ-āĻāϞāĻž āĻāύāϏā§āĻāĻŋāĻāĻŋāĻāĻāĨ¤ |
| Prescription date | āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāϤā§āϰ | 18 October 2026 â ā§§ā§Ž āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤ |
| Radiology facility | āĻĒāϰā§āĻā§āώāĻž | Popular Diagnostic Centre, Jatrabari Branch; X-ray dated 12 October 2026. |
| Registration / room | āϰā§āĻāĻŋ/āĻāĻā§āώ | NIENT: 0095709; Room no. 05; token/serial appears 72. |
| Original prescriber | āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻ | Handwritten signature present but name and degree not legible â āύāĻžāĻŽ/āĻĄāĻŋāĻā§āϰāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻĒāĻžāĻ āϝā§āĻā§āϝ āύā§āĨ¤ |
| X-ray referral | āĻāĻā§āϏ-āϰ⧠āϰā§āĻĢāĻžāϰ | Asso. Prof. Dr. Tariqul Islam (Tareq), MBBS, BCS (Health), FCPS (ENT), MS (ENT), as stated on radiology report; not established as author of this later prescription. |
Publication privacy note | āĻĒā§āϰāĻāĻžāĻļāύāĻžāϰ āĻā§āĻĒāύā§ā§āϤāĻž: ā§§ā§Ļ āĻŦāĻāϰā§āϰ āĻļāĻŋāĻļā§āϰ āύāĻžāĻŽ āĻ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞā§āϰ āĻĒāϰāĻŋāĻā§ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāύā§āϝ āĻ āĻāĻŋāĻāĻžāĻŦāĻā§āϰ āĻāĻĒāϝā§āĻā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰā§āύāĨ¤
02. C/C and clinical history | āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ āĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
Documented C/C (Chief Complaint) | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ: āĻā§āύ⧠āĻĒā§āĻĨāĻ chief-complaint section āĻŦāĻž āĻāĻĒāϏāϰā§āĻā§āϰ āĻŦāϰā§āĻŖāύāĻž āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤ Confidence 0.98
| Parameter | Source finding | āĻā§āϏ⧠āϝāĻž āĻāĻā§ | Clinical assessment | āĻŦā§āϝāĻžāĻā§āϝāĻž |
|---|---|---|
| C/C | āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ | Not written | āϞā§āĻāĻž āύā§āĻ | Nasal blockage, snoring, sore throat, ear pain/hearing loss must be elicited, not asserted â āĻāϏāĻŦ āĻāĻŋāĻā§āĻāĻžāϏāĻž āĻāϰāϤ⧠āĻšāĻŦā§, āϰā§āĻā§ āĻŦāϞā§āĻā§āύ āĻŦāϞ⧠āϞā§āĻāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤ |
| I/H | Illness history | Not written | āϞā§āĻāĻž āύā§āĻ | Duration of fever, cold, nasal obstruction, throat/ear symptoms unknown â āĻ āĻāĻžāύāĻžāĨ¤ |
| O/H | Operative history | Not written | āϏāĻžāϰā§āĻāĻžāϰāĻŋāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻžāĨ¤ |
| D/H | Drug history | Not written | āĻāĻā§ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ/āϏā§āĻā§āϰā§ā§āĻĄ āύā§āĻā§āĻž āĻ drug allergy āĻ āĻāĻžāύāĻžāĨ¤ |
| M/H | Medical history | Not written | āĻ ā§āϝāĻžāĻāĻŽāĻž, āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āϰā§āĻ āĻ āĻāĻžāύāĻžāĨ¤ |
| O/S/E | Otoscopic examination | Possible ear diagnoses noted, objective findings absent | āĻāĻžāύā§āϰ āĻĒāϰā§āĻĻāĻžāϰ āϰāĻ/āĻĢā§āϞāĻž/āϤāϰāϞ/āύā§āĻžāĻā§āĻž āϞā§āĻāĻž āύā§āĻāĨ¤ |
| O/G/E | General examination | Not written | Vital signs, weight, SpOâ, throat/tonsil grade not recorded. |
| Family / exposure / immunisation | Not written | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ, āϧā§āĻŽāĻĒāĻžāύ āĻāĻā§āϏāĻĒā§āĻāĻžāϰ āĻ āĻāĻŋāĻāĻžāĻĻāĻžāύ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻžāĨ¤ |
Working symptom hypotheses | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĒāϏāϰā§āĻ: āύāĻžāĻ āĻŦāύā§āϧ, āύāĻžāĻ āĻĄāĻžāĻāĻž, āĻŽā§āĻ āĻĻāĻŋā§ā§ āĻļā§āĻŦāĻžāϏ, āĻāϞāĻž āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻāĻžāύ⧠āϏāĻŽāϏā§āϝāĻž āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§âāĻāĻā§āϞ⧠āĻāώā§āϧ āĻ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻĻā§āĻā§ āĻ āύā§āĻŽāĻžāύ; āύāĻŋāĻļā§āĻāĻŋāϤ C/C āύā§āĨ¤ Confidence 0.50
03. Original physician’s diagnosis | āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§
- âAdeno-Tonsillitisâ â āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻ āĻĒā§āϝāĻžāϞāĻžāĻāĻžāĻāύ āĻāύāϏāĻŋāϞā§āϰ āĻĒā§āϰāĻĻāĻžāĻš; āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻšāĻžāϤ⧠āϞā§āĻāĻž āĻšāĻŋāϏā§āĻŦā§ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āϏā§āĻĒāώā§āĻāĨ¤ Confidence 0.90
- âAOM (R?)â â āϏāĻŽā§āĻāĻŦāϤ āĻĄāĻžāύ āĻāĻžāύā§āϰ Acute Otitis Media (āϤā§āĻŦā§āϰ āĻŽāϧā§āϝāĻāϰā§āĻŖā§āϰ āĻĒā§āϰāĻĻāĻžāĻš)āĨ¤ āĻļāĻŦā§āĻĻ/āĻĒāĻžāĻļ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ Confidence 0.58
- âOME (Lt?)â â āϏāĻŽā§āĻāĻŦāϤ āĻŦāĻžāĻŽ āĻāĻžāύā§āϰ Otitis Media with Effusion (āĻŽāϧā§āϝāĻāϰā§āĻŖā§ āĻĒā§āϰāĻĻāĻžāĻšāĻšā§āύ/āĻ -āϤā§āĻŦā§āϰ āϤāϰāϞ āĻāĻŽāĻž)āĨ¤ āĻĒāĻžāĻļ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ Confidence 0.72
Safety distinction: AOM = acute bacterial/viral inflammatory ear syndrome; OME = middle-ear effusion without acute infection findings. āĻāĻāĻ āĻ āĻŦāϏā§āĻĨāĻž āύā§āĨ¤ āĻāĻā§āϏ-āϰ⧠āύāĻžāϏā§āĻĢā§āϝāĻžāϰāĻŋāĻāĻā§āϏā§āϰ; āĻāĻāĻŋ āĻāĻžāύ āĻŦāĻž āĻāύāϏāĻŋāϞā§āϰ āϰā§āĻ āϏā§āĻŦāĻžāϧā§āύāĻāĻžāĻŦā§ āĻĒā§āϰāĻŽāĻžāĻŖ āĻāϰ⧠āύāĻžāĨ¤
04. O/E and clinical findings | āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ
Written observations: āύāĻžāϏāĻžāϞ/āĻĢā§āϝāĻžāϰāĻŋāĻā§āĻāĻŋā§āĻžāϞ āĻāύā§āĻĄā§āϏā§āĻāĻĒāĻŋ, āĻāύāϏāĻŋāϞā§āϰ grade, temperature, eardrum findings, auscultation, vitals āĻŦāĻž weight āĻā§āύāĻāĻāĻŋ āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤ Confidence 0.97
Clinician should record: bilateral pneumatic otoscopy (āĻĻā§āĻ āĻāĻžāύā§āϰ āĻĒāϰā§āĻĻāĻžāϰ āĻāϞāύ āĻĒāϰā§āĻā§āώāĻž), ear canal, tonsillar size/exudate, nasal discharge, turbinates, adenoid symptoms, neck nodes, sleep-related breathing, hearing and speech, vital signs, weight and hydration. Confidence 0.95 (guideline standard)
05. Investigations: report 1 and report 2 | āϰāĻŋāĻĒā§āϰā§āĻ āĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ
| Source | āύāĻĨāĻŋ | Original English | āĻāĻāϰā§āĻāĻŋ | Bangla clinical meaning | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž |
|---|---|---|
| Report 1: Written X-ray, 12-10-2026 | âSoft tissue swelling is seen in posterior wall nasopharynx.â | āύāĻžāϏā§āĻĢā§āϝāĻžāϰāĻŋāĻāĻā§āϏā§āϰ āĻĒā§āĻāύā§āϰ āĻĻā§ā§āĻžāϞ⧠āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āĻŦā§āĻĻā§āϧāĻŋ/āĻĢā§āϞāĻžāĻāĻžāĻŦāĨ¤ |
| Report 1 | âNasopharyngeal air column is mild to moderately compressed.â | āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžā§ā§āĻĒāĻĨ āĻŽā§āĻĻā§ āĻĨā§āĻā§ āĻŽāĻžāĻāĻžāϰāĻŋ āϏāϰā§āĨ¤ |
| Report 1 | âCervical spine appears normal.â | āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻāϞāĻžāϰ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāĨ¤ |
| Report 1 | âMild to moderate adenoid hypertrophy.â | āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻŽā§āĻĻā§ āĻĨā§āĻā§ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŦā§ āĻšāĻā§āĻžāϰ āϰā§āĻĄāĻŋāĻāϞāĻāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤāĨ¤ |
| Report 2: Film photograph | Lateral nasopharyngeal X-ray film; glare and angle limit independent grading. | āĻāĻā§āϏ-āϰ⧠āĻĢāĻŋāϞā§āĻŽā§āϰ āĻŽā§āĻŦāĻžāĻāϞ āĻāĻŦāĻŋāϤ⧠āĻĒā§āϰāϤāĻŋāĻĢāϞāύ; āύāĻŋāϰā§āĻā§āϞ āĻā§āϰā§āĻĄ/āĻŦāĻžāϧāĻžāϰ āĻļāϤāĻāϰāĻž āĻšāĻŋāϏāĻžāĻŦ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤ |
| Prescription investigation/advice | Possibly âPTA + SRT + medicalâ (handwriting uncertain). | PTA = Pure Tone Audiometry (āĻļā§āϰāĻŦāĻŖāĻŽāĻžāϤā§āϰāĻž āĻĒāϰā§āĻā§āώāĻž); SRT = Speech Reception Threshold (āĻāĻĨāĻž āĻļā§āύ⧠āĻŦā§āĻāĻžāϰ āϏā§āĻŽāĻž); āĻĒāϰā§āĻā§āώāĻž āĻĻā§āĻā§āĻž/āĻļā§āώ āĻšā§ā§āĻā§âāϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ |
Important: Only adenoid hypertrophy is corroborated by radiology. Tonsillitis, AOM and OME require separate clinical examination. Confidence 0.97
06. Definition | āϰā§āĻā§āϰ āϏāĻāĻā§āĻāĻž
Adenoid hypertrophy â āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ lymphoid tissue āĻŦāĻž pharyngeal tonsil āĻāĻāĻžāϰ⧠āĻŦā§ āĻšāĻā§āĻž; āĻāĻŋāĻā§ āĻā§āώā§āϤā§āϰ⧠āύāĻžāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻŦāĻžā§ā§āĻĒāĻĨ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻšā§āĨ¤ Confidence: 0.98
Adenotonsillitis â āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻ āĻĒā§āϝāĻžāϞāĻžāĻāĻžāĻāύ āĻāύāϏāĻŋāϞā§āϰ āĻĒā§āϰāĻĻāĻžāĻš/āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻ āĻŦāϏā§āĻĨāĻž; āĻŦāϰā§āϧāĻŋāϤ āĻāĻāĻžāϰ āĻĨāĻžāĻāĻž āĻŽāĻžāύā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āύā§āĨ¤ Confidence: 0.98
Acute otitis media (AOM) â āĻŽāϧā§āϝāĻāϰā§āĻŖā§āϰ āϤā§āĻŦā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖ; āĻāĻžāύā§āϰ āĻĒāϰā§āĻĻāĻžā§ characteristic bulging/effusion āĻĒā§āϰā§ā§āĻāύāĨ¤ Confidence: 0.98
Otitis media with effusion (OME) â āϤā§āĻŦā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϞāĻā§āώāĻŖ āĻāĻžā§āĻž āĻŽāϧā§āϝāĻāϰā§āĻŖā§ āϤāϰāϞ āĻāĻŽāĻžāĨ¤ Confidence: 0.98
07. Etiology and pathophysiology | āĻāĻžāϰāĻŖ āĻ āϰā§āĻāϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
- Age-related lymphoid growth | āĻŦā§āϏ-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āϞāĻŋāĻŽā§āĻĢā§ā§āĻĄ āĻŦā§āĻĻā§āϧāĻŋ: āĻļāĻŋāĻļā§ āĻŦā§āϏ⧠adenoid āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāĻāĻžāĻŦā§āĻ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻŦā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ 0.95
- Repeated viral/bacterial exposure | āĻŦāĻžāϰāĻŦāĻžāϰ āĻā§āĻŦāĻžāĻŖā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļ: āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āĻāĻžāϰāĻŖā§ lymphoid tissue āĻŦā§/āϏā§āĻĢā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§; āĻāĻ āϰā§āĻā§āϰ āĻāĻžāϰāĻŖ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύā§āĨ¤ 0.88
- Rhinitis or allergy | āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ: āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ nasal symptoms āĻŦāĻžā§āĻžāϤ⧠āĻĒāĻžāϰā§; āĻļā§āϧ⧠āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ allergy āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ 0.84
- Eustachian tube dysfunction | āĻāĻžāύā§āϰ āĻŦāĻžāϤāĻžāϏ āĻāϞāĻžāĻāϞā§āϰ āύāĻžāϞāĻŋāϰ āĻ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž: āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ/āύāĻžāϏā§āĻĢā§āϝāĻžāϰāĻŋāĻā§āĻāĻŋā§āĻžāϞ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϏāĻā§āĻā§ OME āϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ 0.92
08. Clinical features and missing data | āĻāĻĒāϏāϰā§āĻ āĻ āĻ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϤāĻĨā§āϝ
| Possible clinical feature | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώāĻŖ | Must be confirmed | āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύ |
|---|---|
| Nasal obstruction â āύāĻžāĻ āĻŦāύā§āϧ | āĻĻāĻŋāύ/āϰāĻžāϤ, āĻāĻ/āĻāĻā§ āĻĻāĻŋāĻ, āĻāϤāĻĻāĻŋāύ? |
| Mouth breathing / snoring â āĻŽā§āĻ āĻĻāĻŋā§ā§ āĻļā§āĻŦāĻžāϏ/āύāĻžāĻ āĻĄāĻžāĻāĻž | āĻā§āĻŽā§ breathing pauses, gasping, restless sleep? |
| Tonsillitis symptoms â āĻāύāϏāĻŋāϞ āĻĒā§āϰāĻĻāĻžāĻš | āĻā§āĻŦāϰ, āĻāϞāĻž āĻŦā§āϝāĻĨāĻž, āĻāĻŋāϞāϤ⧠āĻāώā§āĻ, exudate? |
| AOM â āϤā§āĻŦā§āϰ āĻŽāϧā§āϝāĻāϰā§āĻŖ āĻĒā§āϰāĻĻāĻžāĻš | āĻāĻžāύ⧠āĻŦā§āϝāĻĨāĻž, āĻā§āĻŦāϰ, āĻāĻžāύā§āϰ āĻĒāϰā§āĻĻāĻž āĻĢā§āϞāĻž/āϞāĻžāϞ? |
| OME â āĻāĻžāύ⧠āϤāϰāϞ | āĻļā§āϰāĻŦāĻŖ āĻāĻŽā§ āϝāĻžāĻā§āĻž, āĻāϰāĻžāĻ āĻ āύā§āĻā§āϤāĻŋ, tympanogram? |
| Other alarm signs â āϏāϤāϰā§āĻāϤāĻž | āĻļā§āĻŦāĻžāϏāĻāώā§āĻ, āĻāĻžāĻŦāĻžāϰ/āĻĒāĻžāύāĻŋ āĻāĻŋāϞāϤ⧠āύāĻž āĻĒāĻžāϰāĻž, mastoid tenderness, severe headache? |
āĻāĻā§āϞ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ āύā§āϏāύā§āϧāĻžāύā§āϰ āϤāĻžāϞāĻŋāĻāĻž; āϏā§āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āϞāĻŋāĻāĻŋāϤ symptom āύā§āĨ¤ Source completeness 0.98
09. Differential diagnosis | āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻāύāĻŋāϰā§āĻŖā§
- Allergic rhinitis â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš; sneezing, nasal itch, watery discharge.
- Recurrent viral upper respiratory infection â āĻŦāĻžāϰāĻŦāĻžāϰ āĻāĻžāĻāϰāĻžāϞ āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Bacterial tonsillopharyngitis â āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āĻāύāϏāĻŋāϞ/āĻāϞāĻžāĻŦā§āϝāĻĨāĻž; āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠GAS testāĨ¤
- Chronic adenoiditis â āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Turbinate hypertrophy / sinus disease â āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻāĻŋāϏā§āϝ⧠āĻŦā§ āĻŦāĻž āϏāĻžāĻāύāĻžāϏā§āϰ āϰā§āĻāĨ¤
- Tonsillar hypertrophy with sleep-disordered breathing â āĻāύāϏāĻŋāϞ āĻŦā§ āĻšāĻā§āĻžā§ āĻā§āĻŽā§ āĻļā§āĻŦāĻžāϏ⧠āĻŦāĻžāϧāĻžāĨ¤
Final differentiation: Nasopharyngeal X-ray alone cannot classify the cause of sore throat or ear disease. 0.96
10. Prescribed drugs: transcription and verification | āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧā§āϰ āϤāĻžāϞāĻŋāĻāĻž āĻ āϝāĻžāĻāĻžāĻ
| # | Handwritten interpretation | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāώā§āϧ | Generic | āĻŽā§āϞ āĻāĻĒāĻžāĻĻāĻžāύ | Identification | āύāĻŋāĻļā§āĻāĻŋāϤāϤāĻžāϰ āĻŽāĻžāϤā§āϰāĻž |
|---|---|---|---|
| 1 | Clacido 375 (looks Clacido/Clavido) | Amoxicillin 250 mg + Clavulanic acid 125 mg | High â 0.86 |
| 2 | Xalcort 18 | Deflazacort 18 mg | High â 0.94 |
| 3 | Paricel 10 (name difficult) | Rabeprazole sodium 10 mg if correctly read | Moderate â 0.72 |
| 4 | Afrin N/D (strength unclear) | Oxymetazoline; 0.05% vs 0.025% not established | High for name â 0.89 |
| 5 | Momes- nasal spray (Momeson / Momespray cannot be distinguished) | Likely mometasone furoate 50 mcg/spray | Moderate â 0.72 |
| 6 | Trilock 5 | Montelukast 5 mg | High â 0.91 |
Prescription dose caveat: āϰā§āĻāĻŋāĻŽā§āύā§āϰ āĻāĻŋāĻā§ āϏāĻāĻā§āϝāĻž āĻšāĻžāϤ⧠āϞā§āĻāĻž āĻ āϏā§āĻĒāώā§āĻāĨ¤ Clacido āϏāĻŽā§āĻāĻŦāϤ ā§§+ā§§+ā§§, Xalcort āϏāĻŽā§āĻāĻŦāϤ ā§§+ā§Ļ+ā§Ļ, Paricel ā§§+ā§Ļ+ā§§ āĻāĻŦāĻ Trilock ā§Ļ+ā§Ļ+ā§§; āĻāĻŋāύā§āϤ⧠weight āĻ pharmacy label āĻāĻžā§āĻž āĻāĻā§āϞ⧠āĻ āύā§āϏāϰāĻŖāϝā§āĻā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻĻā§āĻļ āύā§āĨ¤ āĻŦāĻŋāĻļā§āώ āĻāϰ⧠intranasal mometasone-āĻāϰ āĻāĻžāĻĒ āĻ āĻĻā§āύāĻŋāĻ āĻŦāĻžāϰ āĻ āĻŦāĻļā§āϝāĻ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
11. MedEx individual medicine reviews â 17 parameters each | āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāώā§āϧā§āϰ ā§§ā§āĻāĻŋ āϤāĻĨā§āϝ
1. Clacido 375 mg â āĻā§āϞāĻžāϏāĻŋāĻĄā§ Identification confidence: 0.86
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Amoxicillin 250 mg + Clavulanic acid 125 mg â āĻ ā§āϝāĻžāĻŽāĻā§āϏāĻŋāϏāĻŋāϞāĻŋāύ āĻ āĻā§āϞāĻžāĻā§āϞāĻžāύā§āĻāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Clacido 375 mg (Healthcare Pharmaceuticals Ltd.) â āĻšāĻžāϤ⧠āϞā§āĻāĻž āύāĻžāĻŽā§āϰ āϏāĻŦāĻā§ā§ā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽāĻŋāϞāĨ¤
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Moxaclav 250/125, Augment 250/125, Clamox 250/125 â āĻāĻāĻ āĻāĻĒāĻžāĻĻāĻžāύā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĨ¤
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Broad spectrum penicillins â āĻŦāĻŋāϏā§āϤā§āϤ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻžāϰ āĻĒā§āύāĻŋāϏāĻŋāϞāĻŋāύāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Beta-lactam antibiotic + beta-lactamase inhibitor â āĻŦāĻŋāĻāĻž-āϞā§āϝāĻžāĻāĻāĻžāĻŽ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āĻ āĻāύāĻāĻžāĻāĻŽ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻāĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
Bacterial ENT infections, selected otitis media/tonsillitis â āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āĻŦāĻž āϏāύā§āĻĻā§āĻšāϝā§āĻā§āϤ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
āϏāĻŽā§āĻāĻžāĻŦā§āϝ AOM/āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ tonsillitis āĻā§āĻŦā§ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§; āϤāĻŦā§ otoscopy āĻŦāĻž throat-test āĻĢāϞ āύā§āĻāĨ¤
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Diarrhoea, nausea, rash; rarely anaphylaxis, antibiotic-associated colitis, liver injury â āĻĒāĻžāϤāϞāĻž āĻĒāĻžā§āĻāĻžāύāĻž, āĻŦāĻŽāĻŋ, āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, āĻŦāĻŋāϰāϞ āĻā§āϰā§āϤāϰ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
Clacido â MedEx brand
Amoxicillin + Clavulanic acid â MedEx generic
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
MedEx currently displays ā§ŗ30/tablet, ā§ŗ180/6-tablet strip, ā§ŗ540/18-tablet pack; some indexed snapshots show ā§ŗ25/tablet: live price may vary. āĻ āύā§āϝ āĻļāĻā§āϤāĻŋ 625 mg, 1 g; oral suspension āĻ injectionāĨ¤
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Amoxicillin inhibits bacterial cell-wall cross-linking; clavulanate blocks some beta-lactamases â āĻā§āώāĻĒā§āϰāĻžāĻā§āϰ āϤā§āϰāĻŋāϤ⧠āĻŦāĻžāϧāĻž āĻ āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻāύāĻāĻžāĻāĻŽ āĻĻāĻŽāύāĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
Selected susceptible bacterial ENT, respiratory, urinary, skin, soft tissue infections â āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Penicillin allergy and previous co-amoxiclav cholestatic jaundice contraindications; interactions with warfarin, allopurinol, methotrexate â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āϞāĻŋāĻāĻžāϰ āϏāĻŽāϏā§āϝāĻžā§ āϏāϤāϰā§āĻāϤāĻžāĨ¤
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
Weight, renal function, allergy and prior antibiotic history essential; antibiotic stewardship â āĻāĻāύ, āĻāĻŋāĻĄāύāĻŋ āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
Possible Rx transcription: 1+1+1 for ~7 days (NOT confirmed). Ten-year-old dosage must be weight-based, not adult tablet schedules; verify amoxicillin/clavulanate ratio, indication and dosing with prescriber before giving.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Patient male child: not applicable; generally use in pregnancy/lactation only under clinician assessment.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
250/125, 500/125, 875/125 tablets; (125/31.25)/5 mL and (400/57.5)/5 mL suspension; 600 mg and 1.2 g injections.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āϰāĻŋāĻĒā§āϰā§āĻā§ adenoid āĻŦā§ āĻšā§ā§āĻā§âāĻāĻāĻŋ āĻāĻāĻžāĻ antibiotic indication āύā§āĨ¤ āϏāϤā§āϝāĻŋāĻāĻžāϰā§āϰ AOM āĻšāϞ⧠drug choice/dose āĻāĻāύ āĻ history-āύāĻŋāϰā§āĻāϰ; āĻā§āĻŦāϞ OME āĻšāϞ⧠antibiotic āϏāĻžāϧāĻžāϰāĻŖāϤ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āύā§āĨ¤
2. Xalcort 18 mg â āĻā§āϞāĻāϰā§āĻ Identification confidence: 0.94
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Deflazacort 18 mg â āĻĄā§āĻĢāϞāĻžāĻāĻžāĻāϰā§āĻāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Xalcort 18 mg, Beacon Pharmaceuticals PLC â āĻŦā§āĻāύāĨ¤
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Defcort, Deflacort, Deflazit (same generic; strength availability varies) â āĻŦāĻŋāĻāϞā§āĻĒāĨ¤
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Glucocorticoids â āĻā§āϞā§āĻā§āĻāϰā§āĻāĻŋāĻā§ā§āĻĄāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Systemic corticosteroid â āϏāĻžāϰāĻž āĻļāϰā§āϰ⧠āĻāĻžāĻ āĻāϰ⧠āĻāĻŽāύ āϏā§āĻā§āϰā§ā§āĻĄāĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
Severe allergic/inflammatory or other steroid-responsive conditions â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻā§āĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
āĻāύāϏāĻŋāϞ/āύāĻžāϏāĻžāϞ āĻĒā§āϰāĻĻāĻžāĻš āĻĻā§āϰā§āϤ āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻšāϤ⧠āĻĒāĻžāϰā§; āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠indication āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĨ¤
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
GI upset, mood/sleep changes, increased glucose, infection risk, adrenal suppression with longer exposure â āĻĒāĻžāĻāϏā§āĻĨāϞā§/āĻā§āĻŽ/āϰāĻā§āϤā§āϰ āϏā§āĻāĻžāϰ/āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻā§āĻāĻāĻŋāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
ā§ŗ20/tablet; 3 x 10 = ā§ŗ600; 10-tablet equivalent ā§ŗ200 (MedEx page does not explicitly display a strip price). Forms: 6, 18, 24, 30, 36 mg; suspension 6 mg/5 mL.
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Glucocorticoid receptor effects inhibit inflammatory mediator expression â āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϰāĻžāϏāĻžā§āύāĻŋāĻ āĻŦāĻžāϰā§āϤāĻž āĻāĻŽāĻžā§āĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
Specific severe allergic, autoimmune and inflammatory conditions (not routine isolated adenoid enlargement) â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āĨ¤
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Drug interactions: rifampicin, anticonvulsants, azole antifungals; live vaccines during significant immunosuppression; systemic fungal infection and hypersensitivity need attention.
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
Assess infection, diabetes risk, exposure to other steroids, immunisation status; do not extend or abruptly stop long courses without review.
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
Handwriting appears 18 mg once in morning for short course; duration unclear. In children dose depends on weight and indication. Guideline does not endorse routine systemic steroids solely for adenoid hypertrophy/OME.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Not applicable to 10-year-old male; crosses placenta and breastmilk caution for relevant adults.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
6,18,24,30,36 mg tablets and 6 mg/5 mL suspension; same generic non-combination forms.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āĻāĻāĻ āĻļāĻŋāĻļā§āϰ systemic Xalcort + intranasal mometasone āĻāĻāϏāĻā§āĻā§ āĻĨāĻžāĻāϞ⧠āĻŽā§āĻ steroid exposure āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻĒā§āϰā§ā§āĻāύ; routine adenoid/OME treatment āĻšāĻŋāϏā§āĻŦā§ systemic steroid āϝāĻĨāĻžāϰā§āĻĨ āύā§āĨ¤
3. Paricel 10 mg â āĻĒā§āϝāĻžāϰāĻŋāϏā§āϞ (probable) Identification confidence: 0.72
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Rabeprazole sodium 10 mg â āϰâā§āϝāĻžāĻŦā§āĻĒā§āϰāĻžāĻāϞāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Paricel 10 mg EC tablet, ACI Limited; handwritten name not fully definite.
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Tagus 10 mg and other rabeprazole brands (MedEx generic list check before substitution) â āĻŦāĻŋāĻāϞā§āĻĒāĨ¤
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Proton Pump Inhibitor â āĻĒā§āϰā§āĻāύ āĻĒāĻžāĻŽā§āĻĒ āĻāύāĻšāĻŋāĻŦāĻŋāĻāĻžāϰāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Gastric acid secretion inhibitor â āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϏāĻŋāĻĄ āĻāĻŽāĻžāύ⧠āĻāώā§āϧāĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
GERD, peptic ulcer or defined acid-related symptoms â āĻ āĻŽā§āϞāϤāĻž/āϰāĻŋāĻĢā§āϞāĻžāĻā§āϏ/āĻāϞāϏāĻžāϰāĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
Oral steroid/medicine-āĻāϰ āϏāĻā§āĻā§ gastric symptoms āĻā§āĻŦā§ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§; epigastric symptoms documented āύā§āĨ¤
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, diarrhoea, abdominal pain, nausea; prolonged use may cause mineral deficiency and C. difficile risk â āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž/āĻĒā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻāϤā§āϝāĻžāĻĻāĻŋāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
ā§ŗ3.51/tablet; ā§ŗ35.10/10-tablet strip; 10 x 10 pack ā§ŗ351. Other: 20 mg EC tablet/capsule.
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Blocks parietal cell H+/K+-ATPase to lower gastric acid â āĻāϏāĻŋāĻĄ āĻā§āĻĒāĻžāĻĻāύā§āϰ āĻā§ā§āĻžāύā§āϤ āϧāĻžāĻĒ āĻŦāύā§āϧ āĻāϰā§āĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
GERD, ulcers, selected H. pylori regimens, acid hypersecretory conditions â āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻāĨ¤
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Drug absorption interactions (ketoconazole/itraconazole), avoid atazanavir; hypersensitivity caution.
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
Not routinely indicated simply for short-course steroid use in a healthy child. Product page contains internally inconsistent paediatric messaging; verify specific formulation indication.
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
Handwriting may be 1+0+1; this is not confirmed. MedEx paediatric GERD dosing discussion typically once daily by weight; a 10-year-old should not be given twice daily solely on uncertain handwriting.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Not applicable to 10-year-old male; manufacturer cautions for pregnancy/breastfeeding.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
10 mg EC tablet, 20 mg EC tablet, 20 mg EC capsule; no routine combination confirmed on brand page.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āĻāĻāĻŋ āĻāĻžāύā§āϰ āĻŦāĻž āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄā§āϰ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĨ¤ āĻā§āϝāĻžāϏā§āĻā§āϰāĻŋāĻ āĻāĻĒāϏāϰā§āĻ/GERD āύāĻž āĻĨāĻžāĻāϞ⧠āĻĒā§āϰā§ā§āĻāύ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§; ā§§ā§Ļ āĻŦāĻāϰ āĻŦā§āϏ⧠formulation āĻāĻŦāĻ dosing āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āϝāĻžāĻāĻžāĻāϝā§āĻā§āϝāĨ¤
4. Afrin nasal drops â āĻāĻĢāϰāĻŋāύ āύāĻžāĻā§āϰ āĻĄā§āϰāĻĒ Identification confidence: 0.89 (brand), <0.5 (strength)
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Oxymetazoline hydrochloride â āĻ āĻā§āϏāĻŋāĻŽā§āĻāĻžāĻā§āϞāĻŋāύāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Afrin nasal drops, Aristopharma Ltd.; concentration handwriting unclear (0.05% adult/âĨ6y or 0.025% lower strength).
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Azolin, Congenil, Nasoclin, Oxrin, Nasalox (appropriate matching strength required).
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Nasal Anti-histamine preparations, Nasal Decongestants & Other Nasal Preparations â MedEx āĻļā§āϰā§āĻŖāĻŋāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical alpha-adrenergic sympathomimetic vasoconstrictor â āύāĻžāĻā§āϰ āϰāĻā§āϤāύāĻžāϞāĻŋ āϏāĻāĻā§āĻāĻŋāϤāĻāĻžāϰā§āĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
Short-term nasal congestion relief â āϏāĻžāĻŽā§āĻŋāĻ āύāĻžāĻ āĻŦāύā§āϧ āĻāĻĒāĻļāĻŽāĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ mucosal swelling āĻāĻŽāĻŋā§ā§ āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰāĻžāϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Dryness, burning, rebound congestion, rarely palpitations/BP changes â āύāĻžāĻ āĻā§āĻŦāĻžāϞāĻž, āĻŦāĻžāϰāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠āĻāϰāĻ āĻŦāύā§āϧ āĻšāĻā§āĻžāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
Oxymetazoline nasal preparation â MedEx
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
MedEx: Afrin 0.05% 10 mL ā§ŗ70; 0.025% 10 mL ā§ŗ65. Bottle price; strip/unit-tablet price not applicable.
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Alpha-receptor stimulation constricts nasal mucosal arterioles â āύāĻžāĻā§āϰ āĻĢā§āϞāĻž āĻāĻŽāĻžā§āĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
Symptomatic congestion due to cold/rhinitis/sinusitis â āĻāĻĒāϏāϰā§āĻ āĻāĻĒāĻļāĻŽāĨ¤
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
MAO inhibitors or some antidepressants, hypersensitivity, cardiovascular disease/thyroid disease/glaucoma require caution.
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
Rhinitis medicamentosa with repeated/prolonged use; avoid use beyond 3â5 days without clinician assessment.
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
Concentration and number of drops on photograph cannot be read reliably; do not translate into a usable order until checked on original or pharmacy dispensing label.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Not applicable to 10-year-old male; generally caution in pregnancy/lactation.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
0.025% and 0.05% nasal-drop preparations; oxymetazoline also exists as nasal sprays from other brands.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āĻļā§āϧ⧠āĻ āϞā§āĻĒ āĻĻāĻŋāύā§āϰ āĻāĻĒāϏāϰā§āĻ-āĻāĻĒāĻļāĻŽā§āĨ¤ OME āϏāĻžāϰāĻŋā§ā§ āϤā§āϞ⧠āύāĻž; āĻĻā§āϰā§āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠rebound congestion āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
5. Momes- nasal spray â āϏāĻŽā§āĻāĻŦāϤ Momeson / Momespray Identification confidence: 0.72
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Mometasone furoate 50 mcg/spray (probable) â āĻŽā§āĻŽā§āĻāĻžāϏā§āύ āĻĢāĻŋāĻāϰā§ā§ā§āĻāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Handwritten âMomeâĻâ: Momeson (Incepta) or Momespray (Navana) possible; cannot prove which brand.
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Metaspray, Metamist, Nasomet, Nasonex, M-Son (same active ingredient/strength).
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Nasal Steroid Preparations â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āϏā§āĻā§āϰā§ā§āĻĄāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical corticosteroid / glucocorticoid â āϏā§āĻĨāĻžāύā§ā§ āĻĒā§āϰāĻĻāĻžāĻšāύāĻžāĻļāĻ āϏā§āĻā§āϰā§ā§āĻĄāĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
Allergic rhinitis with nasal congestion and sneezing â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϤā§āĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
Coexisting rhinitis or nasal inflammatory swelling management may be reason; allergy has not been documented.
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Epistaxis, nasal irritation, headache, rarely septal injury, systemic absorption with higher/long-term dose â āύāĻžāĻ āĻĻāĻŋā§ā§ āϰāĻā§āϤ/āĻā§āĻŦāĻžāϞāĻžāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
Momeson â MedEx
Momespray â MedEx
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
Either Momeson or Momespray 50 mcg/spray: 120 metered sprays bottle ā§ŗ250 (not per strip).
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Anti-inflammatory corticosteroid action reduces local cytokine-mediated inflammation â āύāĻžāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžā§āĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
Allergic rhinitis (age âĨ2), some nasal polyp indications in adults; off-label benefit may occur in selected adenoid enlargement.
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Strong CYP3A4 inhibitors can raise systemic steroid exposure; avoid known hypersensitivity; combined steroids warrant review.
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
Correct technique: aim away from nasal septum. Assess epistaxis and recent nasal surgery. High doses and prolonged use may affect growth.
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
The child (2â11 years) allergic-rhinitis label recommendation is typically one 50 mcg spray into each nostril once daily. The handwritten number of sprays/frequency may be higher or not decipherable; verify before use. This is generic labelled guidance, not authorisation to replace the patient’s order.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Not applicable to 10-year-old male; pregnancy/lactation risk-benefit assessment for adults.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
50 mcg/spray mometasone nasal brands; other mometasone forms (cream, ointment, inhaled) are not interchangeable for nasal use.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āϝāĻĻāĻŋ âāĻĒā§āϰāϤāĻŋ āύāĻžāĻ⧠⧍ āĻāĻžāĻĒ āĻĻāĻŋāύ⧠⧍ āĻŦāĻžāϰâ āϞā§āĻāĻž āĻšā§ā§ āĻĨāĻžāĻā§, ā§§ā§Ļ āĻŦāĻāϰ āĻŦā§āϏ⧠allergic-rhinitis labelled dose-āĻāϰ āĻā§ā§ā§ āĻŦā§āĻļāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋāϏā§āĻ/āĻĒā§āϰā§āϏāĻā§āϰāĻžāĻāĻŦāĻžāϰā§āϰ āϏāĻā§āĻā§ āĻ āĻŦāĻŋāϞāĻŽā§āĻŦā§ āĻŽāĻŋāϞāĻŋā§ā§ āύā§āĻā§āĻž āĻĻāϰāĻāĻžāϰāĨ¤
6. Trilock 5 mg â āĻā§āϰāĻžāĻāϞāĻ Identification confidence: 0.91
1. Generic name | āĻā§āύā§āϰāĻŋāĻ
Montelukast sodium 5 mg â āĻŽāύā§āĻāĻŋāϞā§āĻāĻžāϏā§āĻāĨ¤
2. Brand name | āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Trilock 5 mg, Opsonin Pharma Ltd.
3. MedEx alternate brand | āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Monas 5, Montene 5 and other confirmed montelukast brands (verify same formulation) â āĻŦāĻŋāĻāϞā§āĻĒāĨ¤
4. MedEx therapeutic class | āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻā§āϞāĻžāϏ
Leukotriene receptor antagonists â āϞāĻŋāĻāĻā§āĻā§āϰāĻŋā§ā§āύ āϰāĻŋāϏā§āĻĒā§āĻāϰ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻāĨ¤
5. Pharmacological class | āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Selective CysLT1 receptor antagonist â āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āϰāĻŋāϏā§āĻĒā§āĻāϰ āĻŦā§āϞāĻāĻžāϰāĨ¤
6. Use / purpose | āĻāĻĻā§āĻĻā§āĻļā§āϝ
Persistent asthma prevention and selected allergic rhinitis â āĻšāĻžāĻāĻĒāĻžāύāĻŋ/āĻāĻŋāĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻāĨ¤
7. Why possibly prescribed here | āĻāĻ āϰā§āĻā§āϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ
āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻž asthma overlap āĻā§āĻŦā§ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§; āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āϞā§āĻāĻž āύā§āĻāĨ¤
8. Adverse effects | āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, abdominal discomfort, and important mood/behaviour/sleep changes; rare suicidal thoughts â āĻā§āĻŽ/āĻāĻāϰāĻŖ/āĻŽā§āĻāĻžāĻā§ āĻā§āϰā§āϤāϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄā§āĻā§āϏ āϞāĻŋāĻāĻ
Trilock 5 â MedEx
FDA montelukast boxed warning
10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝ āĻĢāϰā§āĻŽ
ā§ŗ8.06/tablet, ā§ŗ112.84/14-tablet strip, ā§ŗ338.52/3Ã14 pack. 4 mg and 10 mg; granules, flash, chewable formulations.
11. Mechanism of action | āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Blocks leukotriene CysLT1 receptors reducing inflammatory airway responses â āϞāĻŋāĻāĻā§āĻā§āϰāĻŋā§ā§āύā§āϰ āĻāĻžāĻ āĻāĻāĻāĻžā§āĨ¤
12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ
Asthma prevention, exercise-induced bronchoconstriction prevention, allergic rhinitis â āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžāĨ¤
13. Interactions and contraindications | āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Hypersensitivity contraindication; interactions with rifampicin/phenobarbital and other enzyme inducers may affect exposure.
14. Precautions and warnings | āϏāϤāϰā§āĻāϤāĻž
FDA boxed warning: neuropsychiatric events; for allergic rhinitis reserve when alternatives ineffective or not tolerated. Not indicated for acute asthma attack.
15. Dose and administration | āĻĄā§āĻ āĻ āĻĒā§āϰā§ā§āĻ
Age 6â14 years: 5 mg orally once daily (confirm tablet formulation and prescriber plan). Handwriting seems nighttime; exact duration unclear.
16. Pregnancy and lactation | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻĻā§āĻā§āϧāĻĻāĻžāύ
Not applicable to 10-year-old male; pregnancy/lactation decisions for relevant adults require medical oversight.
17. Other compositions / combinations on MedEx | āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŽā§āĻĒā§āĻāĻŋāĻļāύ
4 mg, 5 mg, 10 mg tablets; 4 mg granules; 4/5 mg flash tablet; 10 mg chewable tablet per MedEx. No necessary co-formulation.
Critical prescription review | āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž: āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻŦā§ āĻšāĻā§āĻžāϰ āĻāύā§āϝ āĻāĻāĻŋ routine medicine āύā§āĨ¤ āĻā§āĻŦāϞ nasal allergy āĻšāϞ⧠safer alternatives āĻāĻā§ āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āĻĒāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϝā§āĻā§āϤāĻŋ āĻĨāĻžāĻāϤ⧠āĻšāĻŦā§; āĻĒāϰāĻŋāĻŦāĻžāϰāĻā§ mood/sleep adverse effects āĻāĻžāύāĻžāϤ⧠āĻšāĻŦā§āĨ¤
12. Bangladesh medicines used by indication | āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āϰā§āĻāĻā§āĻĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧā§āϰ āĻĻā§āĻŦāĻŋāϤā§ā§ āĻā§āĻŦāĻŋāϞ
āĻāĻ āĻā§āĻŦāĻŋāϞāĻāĻŋ āĻŦāĻŋāĻāϞā§āĻĒ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻļā§āϰā§āĻŖāĻŋāϰ āϤāĻĨā§āϝāĻāĻŋāϤā§āϤāĻŋāĻ āϤāĻžāϞāĻŋāĻāĻž; āĻā§āύāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻāĻ āϏāĻā§āĻā§ āϏāĻŦ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāϰ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύā§āĨ¤ Confidence 0.95
| Clinical indication | āĻ āĻŦāϏā§āĻĨāĻž | Possible generic and Bangladesh brand examples (MedEx) | āĻā§āύā§āϰāĻŋāĻ āĻ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ | Why / limitation | āĻā§āύ/āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž |
|---|---|---|
| Confirmed bacterial AOM in selected cases | Amoxicillin, amoxicillin/clavulanate (Clacido, Moxaclav) | āĻā§āĻŦāĻžāĻŖā§ āϏāĻāĻā§āϰāĻŽāĻŖā§; āĻāĻžāύā§āϰ āĻĒāϰā§āĻā§āώāĻž, āĻŦā§āϏ, severity, āĻāĻāύ āĻ antimicrobial history āĻ āύā§āϝāĻžā§ā§āĨ¤ |
| Confirmed group A streptococcal pharyngitis | Penicillin V / amoxicillin (different MedEx brands) | āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻā§āϏā§āĻ/āϝāĻžāĻāĻžāĻā§ā§āϰ āĻĒāϰ; āĻļā§āϧ⧠tonsils āĻŦā§ āĻĻā§āĻā§āĻ antibiotic āύā§āĨ¤ |
| Allergic rhinitis | Mometasone nasal spray (Momeson/Momespray), fluticasone nasal spray | āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻĒā§āϰāϧāĻžāύ āĻāĻŋāĻāĻŋā§āϏāĻž; dose āĻŦā§āϏ āĻ product-specificāĨ¤ |
| Short-term severe nasal congestion | Oxymetazoline (Afrin), saline nasal spray (NaSal/Nosomist) | Oxymetazoline āĻā§ā§āĻ āĻĻāĻŋāύā§āϰ āĻŦā§āĻļāĻŋ āύā§; saline supportiveāĨ¤ |
| Coexisting asthma / refractory allergic rhinitis | Montelukast (Trilock 5) | Asthma indication āĻŦāĻž āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϝāϰā§āĻĨ allergic rhinitis āĻšāϞā§; neuropsychiatric warningāĨ¤ |
| Fever or throat/ear pain | Paracetamol â age/weight-specific brands | āĻāĻĒāϏāϰā§āĻā§āϰ āĻāύā§āϝ; āĻāĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻŦāĻ āϞāĻŋāĻāĻžāϰā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤ |
| OME alone | No routine antibiotic, antihistamine, systemic or nasal steroid, decongestant | OME-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ, hearing assessment āĻ follow-upāĨ¤ |
13. Doctor-versus-independent diagnosis | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Dx āĻŦāύāĻžāĻŽ āϏā§āĻŦāĻžāϧā§āύ Clinical Assessment
đ§ Physician â Original Dx | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž
- Adeno-Tonsillitis â āĻ ā§āϝāĻžāĻĄāĻŋāύā§-āĻāύāϏāĻŋāϞāĻžāĻāĻāĻŋāϏ (0.90)
- Probable AOM (R?) â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĄāĻžāύ āĻŽāϧā§āϝāĻāϰā§āĻŖā§āϰ āϤā§āĻŦā§āϰ āĻĒā§āϰāĻĻāĻžāĻš (0.58)
- Probable OME (Lt?) â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦāĻžāĻŽ āĻŽāϧā§āϝāĻāϰā§āĻŖā§ āϤāϰāϞ āĻāĻŽāĻž (0.72)
đŠ Independent working Dx | āϏā§āĻŦāĻžāϧā§āύ āĻŽā§āϞā§āϝāĻžā§āύ
- Radiologically supported mild-to-moderate adenoid hypertrophy with nasopharyngeal airway narrowing (J35.2) â āĻŦāĻžā§ā§āĻĒāĻĨ āϏāĻāĻā§āĻāĻŋāϤāϏāĻš āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻŦā§ (0.96)āĨ¤
- Clinician-documented adenotonsillitis, activity/etiology unverified â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻĒā§āϰāĻĻāĻžāĻš, āĻāĻŋāύā§āϤ⧠āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻāĻžāϰāĻŖ āϏā§āĻŦāĻžāϧā§āύāĻāĻžāĻŦā§ āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύ⧠(0.76)āĨ¤
- Possible concomitant AOM / OME â laterality and diagnostic criteria to verify â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāύā§āϰ āϏāĻŽāϏā§āϝāĻž; āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠(0.60)āĨ¤
Concordance | āĻŽāĻŋāϞ: Physician assessment and X-ray both involve adenoidal disease. Difference | āĻ āĻŽāĻŋāϞ: X-ray confirms enlarged adenoids, not bacterial infection, tonsillitis, AOM or OME. The prescriber’s ear findings may be based on undocumented otoscopy. It would be improper to label radiographic hypertrophy alone as proven bacterial adenotonsillitis. 0.96
14. Evidence-based management and safety audit | āĻāĻžāĻāĻĄāϞāĻžāĻāύāĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāύāĻž āĻ āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž
- Adenoid hypertrophy | āĻ ā§āϝāĻžāĻĄāĻŋāύā§ā§āĻĄ āĻŦā§: mild or minimally symptomatic disease â watchful waiting; select coexisting rhinitis may benefit from intranasal corticosteroid; persistent obstructive sleep symptoms/ear morbidity â ENT surgical evaluation. 0.95
- OME | āĻŽāϧā§āϝāĻāϰā§āĻŖā§ āϤāϰāϞ: pneumatic otoscopy/tympanometry; non-at-risk children watchful waiting about 3 months. Systemic antibiotics, systemic/intranasal steroids and decongestants not routinely recommended for OME itself. 0.98
- AOM | āϤā§āĻŦā§āϰ āĻŽāϧā§āϝāĻāϰā§āĻŖ āĻĒā§āϰāĻĻāĻžāĻš: verify bulging eardrum/middle ear effusion and symptoms before antibiotics; age/severity-based choices. 0.96
- Suspected bacterial tonsillitis | āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻāύāϏāĻŋāϞ: history/exam; group A strep testing when indicated. Without confirmatory indication, antibiotics may add harm. 0.96
- Prescription safety: simultaneous oral and nasal steroids, uncertain high-dose nasal spray instructions, unverified 10-year-old tablet antibiotic dose, possible duplicate-day PPI schedule and montelukast boxed warning require reconciliation. 0.98
15. Investigations and follow-up plan | āĻĒāϰāĻŦāϰā§āϤ⧠āĻĒāϰā§āĻā§āώāĻž, āĻĢāϞā§āĻāĻĒ āĻ āϰā§āĻĢāĻžāϰā§āϞ
| Priority | āĻ āĻā§āϰāĻžāϧāĻŋāĻāĻžāϰ | Action | āĻāϰāĻŖā§ā§ | Reason | āĻāĻĻā§āĻĻā§āĻļā§āϝ |
|---|---|---|
| 1 | ENT review with childâs original Rx, X-ray and medication strips â āϏāĻŦ āύāĻĨāĻŋ āύāĻŋā§ā§ ENT āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ | Brand, strength, dose and ear diagnoses āĻŽāĻŋāϞāĻžāύā§āĨ¤ |
| 2 | Pneumatic otoscopy Âą tympanometry â āĻāĻžāύā§āϰ āĻĒāϰā§āĻā§āώāĻž | AOM vs OME āϏā§āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāĻžāϰā§āĻĨāĻā§āϝ āĻāϰāĻžāĨ¤ |
| 3 | PTA Âą age-appropriate hearing assessment â āĻļā§āϰāĻŦāĻŖ āĻĒāϰā§āĻā§āώāĻž | āĻļā§āϰāĻŦāĻŖ āĻāĻŽā§ āĻā§āϞ⧠āĻŦāĻž OME āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāϞā§; prescription note possible PTA/SRTāĨ¤ |
| 4 | Tonsil and nose examination Âą flexible nasopharyngoscopy â āĻāϞāĻž/āύāĻžāĻ āĻĻā§āĻāĻž | Adenoid obstruction, tonsil grade, rhinitis āĻŽā§āϞā§āϝāĻžā§āύāĨ¤ |
| 5 | Sleep history Âą polysomnography â āĻā§āĻŽ āĻ āĻļā§āĻŦāĻžāϏ āĻŽā§āϞā§āϝāĻžā§āύ | Witnessed apnea, significant snoring or complicated OSA concern āĻĨāĻžāĻāϞā§āĨ¤ |
| 6 | Consider GAS testing when clinically indicated â āĻāϞāĻžāϰ āĻā§āĻŦāĻžāĻŖā§ āĻĒāϰā§āĻā§āώāĻž | āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ tonsillitis-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϝāĻžāĻāĻžāĻāĨ¤ |
When urgent: Respiratory distress, cyanosis, profound drowsiness, severe dehydration, postauricular swelling/tenderness, acute facial weakness or severe ear pain with systemic illness â urgent assessment. 0.97
16. Illustrative prescription note and referral | āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĄā§āĻŽā§ āĻ āϰā§āĻĢāĻžāϰā§āϞ
ILLUSTRATIVE CLINICAL NOTE â NOT A DISPENSING PRESCRIPTION āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āύā§āĻâāύāϤā§āύ āĻāώā§āϧā§āϰ āĻŦā§āϧ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύā§
Patient: Md. Mahamud | Age/Sex: 10 years / Male | Source Rx: 18-10-2026
C/C: Not documented â Ask about nasal blockage, snoring, sore throat, otalgia, hearing difficulty.
O/E: Not supplied â Confirm vitals, weight, tonsil grade, nasal examination, bilateral pneumatic otoscopy.
Investigations: Lateral X-ray (12-10-2026): mildâmoderate adenoid hypertrophy with narrowed nasopharyngeal airway; consider tympanometry/PTA as indicated.
Dx (prescription-ready, provisional): Adenoid hypertrophy with radiographic nasopharyngeal airway narrowing (J35.2); physician-documented adenotonsillitis; suspected AOM/OME â laterality and clinical confirmation pending.
Plan: ENT reevaluation; confirm eardrum/tonsil findings and body weight; reconcile Clacido, Xalcort, Paricel, Afrin, mometasone spray and Trilock dosing before any further medicines are taken; targeted therapy after confirmation.
Refer to: Consultant Pediatric ENT / Otolaryngologist â evaluate obstructive symptoms, suspected otitis media and hearing status, and determine need for conservative management vs adenoidectomy/other intervention.
Referral note: âPlease evaluate this 10-year-old boy with X-ray-confirmed mild-to-moderate adenoid hypertrophy and physician-recorded adenotonsillitis/possible middle-ear disease. Kindly confirm otoscopic and nasopharyngeal findings, hearing status, and appropriateness of the current medications and doses.â
Drug orders: None issued by this educational review. Original doses must be verified by the treating clinician/pharmacist.
17. Overview, next steps and verified references | āϏāĻžāϰāĻžāĻāĻļ, āĻāϰāĻŖā§ā§ āĻ āϝāĻžāĻāĻžāĻāĻā§āϤ āϤāĻĨā§āϝāϏā§āϤā§āϰ
Final working conclusion | āĻā§ā§āĻžāύā§āϤ āĻāĻžāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§: Radiologically Supported Mild-to-Moderate Adenoid Hypertrophy with Nasopharyngeal Airway Narrowing (ICD-10-CM J35.2); Physician-Documented Adenotonsillitis; Suspected Concurrent AOM/OME Requiring Otoscopic Confirmation. Confidence 0.96 for X-ray component; â¤0.76 for other components
- Today / āĻāĻāύ: ear and throat examination, review childâs weight, assess respiratory and sleep symptoms.
- Before medicines / āĻāώā§āϧā§āϰ āĻāĻā§: clarify handwritten brand/strength/frequency, especially mometasone spray, antibiotic, oral steroid and PPI; never rely on a photograph to dispense uncertain instructions.
- Follow-up / āĻĢāϞā§āĻāĻĒ: Pediatric ENT with tympanometry/age-appropriate hearing testing if suspected middle-ear effusion; surgical need based on symptoms/complications, not X-ray severity alone.
References | āĻĒāĻžāĻ ā§āϝāĻĒā§āϏā§āϤāĻ, āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ DOI
- Nelson Textbook of Pediatrics, 22nd ed., Elsevier (2024), ear and pediatric upper-airway chapters.
- Cummings Otolaryngology: Head & Neck Surgery, 7th ed., Elsevier (2021), adenotonsillar and otitis media sections.
- Ahmad Z et al. Adenoid hypertrophyâdiagnosis and treatment: the new S2k guideline. HNO. 2023. DOI: 10.1007/s00106-023-01299-6.
- Rosenfeld RM et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngol Head Neck Surg. 2016. DOI: 10.1177/0194599815623467.
- American Academy of Pediatrics. Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013. DOI: 10.1542/peds.2012-3488.
- Barshak MB et al. IDSA 2025 GAS pharyngitis guideline update, published 2026. DOI: 10.1093/cid/ciaf668.
- Nixon GM et al. MIST+ trial. JAMA Pediatr. 2026. DOI: 10.1001/jamapediatrics.2025.5717.
- FDA (2020) montelukast boxed warning.
- LIPU MED website category archive â TC sequence source; brand-level MedEx links are supplied for every item above.
Author | āϞā§āĻāĻ: Md.Rafiqul Islam Lipu
Reviewed: Saturday, 31 October 2026 | 04:22 PM (Bangladesh Time)
Disclosure: This is a source-preserving, educational clinical analysis, not a substitute for examination or a prescription.